risedronic acid has been researched along with Lupus Erythematosus, Systemic in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishida, T | 1 |
| Yoshida, S | 1 |
| Kimura, Y | 1 |
| Fujiki, Y | 1 |
| Kotani, T | 1 |
| Takeuchi, T | 1 |
| Makino, S | 1 |
| Arawaka, S | 1 |
1 other study available for risedronic acid and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study.
Topics: Adult; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Fem | 2018 |